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ABSTRACT
Janus dendrimers are amphiphilic macromolecules that have shown promising potential in the
biomedical field. Due to their unique structure and properties, these branched block copolymers
have the ability to self-assemble into bioinspired spherical nanoaggregates. Because they possess
a hydrophobic and hydrophilic moiety, these aggregates show potential as drug delivery systems
that can transport both hydrophobic and hydrophilic drugs. However, many of the proposed
dendrimer systems suffer from certain weaknesses that hinder their practical usage as clinical
treatment options. Some of these shortcomings include specificity, solubility, size, surface charge,
and mechanical properties. To combat these problems, we synthesized and characterized a library
of PAMAM-fatty acid (PAMAM-FA) hybrid Janus dendrimers that offer solutions to the issues
that traditional dendrimers have. These hybrids have a cationic NH3+, an anionic COO-, and a
neutral OH surface functionality on the PAMAM moiety, and they have been covalently bonded
to fatty acids via click chemistry. These dendrimers show potential in biomedical applications to
enhance specificity and to add biological markers to the surface of the PAMAM branches. The
nanoparticles in aqueous solution were characterized using microscopy (TEM) and light scattering
(DLS), and diameters ranged from 40 to 100 nm. Zeta-potential values ranged from -17.9 mV to
+58.7 mV in accordance with the respective surface functionality. TEM images revealed spherical
morphologies and showed critical aggregate concentrations (CAC) that ranged from 0.92 to 1.9
µmol/L. The results of our study exhibit strong evidence for the potential use of these hybrids in
biomedical applications and clinical settings.
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BACKGROUND AND INTRODUCTION
Researchers have been searching for cancer treatments for decades due to the severity and
prevalence of the disease. Cancer cells divide uncontrollably, they metastasize to other parts of the
body, and they harm surrounding healthy cells by consuming available nutrients. Doctors have
been unable to find a singular cure for all cancer types due to the vast complexity and variability
among them. In addition, it is difficult to target cancer cells specifically. Chemotherapy and
radiation kill cancer cells, but they also kill the surrounding healthy cells. These current methods
and medications have advanced, but they still have their shortcomings such as drug loading
efficiencies, drug releasing efficiencies, biocompatibility, etc. Due to the lack of selectivity, the
many side-effects including hair loss, fatigue, and decreasing immunity often cause additional
problems for patients. In addition to selectivity issues, cancer drugs are typically hydrophobic, so
it is difficult to transport them via the bloodstream to the target site due to their insolubility.
To resolve these problems of specificity, potency, and solubility, scientists have
investigated potential therapies to target cancer sites and minimize the death of healthy cells. One
of these therapies include targeted drug delivery using synthetic molecules. Drug delivery systems
(DDS) have the potential to revolutionize cancer treatments, and they have other biomedical
applications, such as antibiotic therapy1 and gene transfection2. For drug delivery, these vehicles
behave as transports to carry drugs to a specific location to be released at a specific time. Scientists
have the ability to manage the location specificity via the surface modifications on the DDS. They
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can also control the release time and rate through the stability and degradation of the vehicle. These
controllable aspects of drug delivery systems drove research scientists to develop different types
of DDSs and continue to optimize them.
Researchers have been tirelessly searching for candidates for targeted drug delivery, and
there are many vehicles that have been put forth as potential solutions. The ideal DDS is an
amphiphilic nanoparticle that can self-assemble into a stable bilayer vesicle to deliver hydrophilic
and hydrophobic drugs to a specific target site. Many of the current vehicles that have been
synthesized have benefits, but they also have disadvantages. Liposomes are made up of lipids that
can form a bilayer with the potential to house hydrophobic and hydrophilic drugs. However, the
liposome’s lipids do not spontaneously self-assemble. They must be sonicated to take shape, but
this method can destroy the phospholipid rendering it an ineffective strategy.3 Polymeric micelles
are also a well-studied potential vehicle. They are amphiphilic, but rather than a bilayer, they form
a single layer with the hydrophilic heads on the exterior. Although these are easy to prepare, they
have a substantial risk of degrading after they have been administered.3 The early degradation
would cause the drugs to be unleashed too early and kill the healthy cells rather than reaching the
target site.
Another popular type of DDS is a dendrimer. In recent years, dendrimers have become one
of the primary topics of supramolecular chemistry due to their numerous promising medical
applications to solve the previously stated issues. Dendrimers are symmetrical, tree-like
macromolecules that can be synthesized in a variety of ways.4 Some of their benefits include their
tunability and controlled synthesis.5 Traditional dendrimers consist of a central core that allows
for a repeating monomer to branch off and continue to repeat in a systematic way.5 Each additional
monomer on the branches constitutes the next “generation” of that dendrimer. The branches end
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with an exterior functional group that can be modified to reduce toxicity or attach fluorescent
moieties.5

Figure 1.: Traditional G2 PAMAM dendrimer6

Dendrimers have been synthesized with a variety of monomers to form various types of
macromolecules. One well-studied type is a polyamidoamine (PAMAM) dendrimer which has
been studied since it was introduced by Donald A. Tomalia in 1985.7 Figure 1 shows the structure
of a traditional PAMAM dendrimer. It grows symmetrically from the center with repeating methyl
acrylate and ethylenediamine segments to form a globular, symmetric macromolecule.
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Dendrimers show significant potential for future biomedical applications, but they still
have some disadvantages. Some of these include rapid systemic clearance, toxicology issues,
solubility, inefficient drug loading, and uncontrolled drug release.8 To combat these problems, a
new class of dendrimers emerged called Janus dendrimers (JDs).
JDs are unique because they lack the symmetric structure of a traditional dendrimer. In
contrast, they possess two different dendrons, typically one hydrophilic and hydrophobic dendron,
that are connected at the central core. Due to their amphiphilic character, these molecules have the
ability to self-assemble into supramolecular nanoaggregates with a variety of structures, including
tubes, micelles, and bilayer vesicles.5,9
These molecules have been shown to self-assemble into stable nanoaggregates by several
researchers. For example, Percec et. al reported that their bilayer vesicles, or dendrimersomes, had
much better mechanical properties than both liposomes and polymersomes.9 Additionally, Peterca
et. al reported that their dendrimersomes had mechanical properties that are equivalent to vehicles
that are already being used in drug delivery to treat cancer patients.10
Their ability to self-assemble into stable aggregates combined with JDs’ highly
controllable structure allows them to resolve some of the previously stated issues that are
associated with traditional dendrimers. Not only are chemists able to manipulate the outer
functional groups to enhance selectivity, but they can also manipulate the building blocks of the
dendrons to combat cytotoxicity. The self-assembled aggregates have the potential to encapsulate
both hydrophobic and hydrophilic drugs, therefore potentially solving the solubility issue. Their
stronger mechanical properties could resolve the drug loading and release problems, as well. Due
to their amphiphilicity, JDs have the potential to offer solutions to many of the problems that
traditional dendrimers could not overcome.
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Interestingly, there are different types of JDs that have been suggested by various
researchers. Previously, we investigated linear dendritic block copolymers (LDBCs). These
macromolecules possess a branched hydrophilic PAMAM moiety and a linear hydrophobic
moiety. These molecules were studied by manipulating the weight ratio of hydrophilic to
hydrophobic moieties and observing changes in morphology and size. The LDBCs showed
promise as they self-assembled to form bilayer vesicles, which is the ideal shape for biomedical
applications. In addition, the ideal diameter, 50 to 65 nm, was achieved in this study. However,
surface functionalization was not discussed.11 To further expand on this area of study, our goal is
to be able to establish a synthetic route, as well as develop JDs based on PAMAM and FAs as
viable candidates, that will capitalize on the current abilities we have established for JDs and
minimize the current problems we see in polymeric drug delivery systems.

SCIENTIFIC RATIONALE
There are many different types of polymers and dendrimers in literature that have been
used to synthesize JDs. One of the more popular choices is polyamidoamine (PAMAM). We chose
PAMAM because it is well studied in literature and still widely used in DDS research. Because
we are synthesizing JDs, only about a quarter of a traditional PAMAM dendrimer is being used to
create the hydrophilic moiety of our hybrids. It is a highly branched structure, making it more ideal
for drug loading, and it has a highly controlled and systematic synthesis. It also can be terminally
functionalized with various end groups which allows for further potential biomedical applications
and decreased toxicity.12 In addition, PAMAM is made up of repeating methyl acrylate and
ethylenediamine segments that form amide bonds. These bonds resemble the structure of
biological proteins that also possess repeating amide bonds.2,12 These polypeptide-like bonds cause
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this highly branched structure to take on some properties of proteins, sometimes being referred to
as “artificial proteins,” and they have been found to have low mammalian toxicity.2
While PAMAM is used for the hydrophilic portion, the hydrophobic portion is made up of
fatty acids (Figure 2). These molecules are a more familiar term and are a well understood in
biology and medicine. Biologists have known for a long time about their roles in cell membranes
and energy storage in humans.13 Because they are native to the human body, they are
biocompatible and biodegradable, making them a logical candidate to use in the synthesis of
delivery vehicles.14 Like PAMAM, there are also several studies that have been recorded in the
literature about their influence in drug delivery.4,14,15 For example, Silvia Hernández-Ainsa et. al
ionically functionalized their PAMAM G2 dendrimers with fatty acids of varying sizes to
determine the effects on the self-assembling properties of their vehicles.15 Our study also employed
the use of fatty acids to observe their effects on the self-assembling properties, however, our fatty
acids are covalently bonded rather than ionically bonded. Fatty acids can be attached covalently
via esterification to 2,2-bis(hydroxymethyl) propionic acid (bis-MPA) based dendrimers.4 A bisMPA based dendrimer, which is a well-studied type of delivery system, was employed in our
vehicle because using a covalent bond yields a more stable molecule that does not rely on the
number of positive and negative ions.4,16 Additionally, bis-MPA dendrimers are polyesters making
them biodegradable and biocompatible, and their terminal alcohol groups allow it to be protected,
deprotected, and esterified with fatty acids.16 Another advantage of the bis-MPA core is the ability
to manipulate the number of terminal alcohol groups, similar to manipulating the number of
PAMAM terminal groups. With this high level of control, we can do further studies on the impact
of varying ratios of fatty acids by growing or condensing the core to attach more fatty acids.
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Figure 2. Fatty acid portion of the hybrid

Herein, we introduce the novel PAMAM-Bis-MPA-4-Fatty Acid hybrid dendrimer with a
PAMAM-G3 moiety and a Bis-MPA based moiety esterified with 4 fatty acid chains (Figure 3).
As previously stated, PAMAM was a logical choice for the hydrophilic portion due to the extensive
research that has already been conducted by numerous researchers.8,9,10 For this work, we chose to
use generation 3 (G3) for our hybrids. Studies have shown that larger generations of PAMAM
suffer from steric crowding due to excessive branching,12 while smaller generations are too flexible
leading to cargo leaking.17
This macromolecule has been successfully synthesized with three different end groups.
These include a carboxylic acid which becomes anionic in PBS buffer (COO-) at pH = 7.4, a neutral
alcohol (OH), and a cationic amine (NH3+) in Milli Q water at pH = 7.0. For the lipophilic portion,
we introduced the fatty acid side chains on an azide-bis-MPA-4-OH dendron. They have the
potential to increase the mechanical properties and, therefore, the strength and stability of the
nanocarrier due to stronger hydrophobic interactions. The two segments were joined via click
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chemistry. Upon deprotection, the dendrimers become amphiphilic and have the ability to selfassemble into nanoparticles.

Figure 3. The three PAMAM-FA hybrids
8

The design and synthesis of these dendrimers are unique and novel in that they can be
modified with a variety of end groups. The exterior groups on the PAMAM moiety include a
carboxylate, alcohol, and an amine. Each of these groups has a protecting group that can be
removed in the final step of the synthesis. These protecting groups are tert-butyl ester (TBE),
tetrahydropyran (THP), and tert-butoxycarbonyl (BOC). The TBE end group protects the
carboxylic acid, THP protects the neutral alcohol, and BOC protects the amine. These end groups
have exhibited different benefits in various studies. For example, cationic terminal amines have
shown increased uptake,18 anionic nanoparticles have shown higher circulation time in the
bloodstream,19 and neutral nanoparticles have been reported as a successful delivery system
without appreciable toxicity.20
The three different end groups on our vehicles also provide another benefit for potential
use. The terminal carboxylate, amine, and alcohol can be the starting materials to add a variety of
biochemical molecules to the exterior groups on the PAMAM portion of the vehicle. This high
level of specificity with respect to the outer groups is particularly valuable for cancer treatments.
Different types of cancerous cells have different properties, which leads to the difficulty in
synthesizing a single cure. However, our JDs have the potential to be a starting molecule from
which more specific vehicles could be synthesized. In other words, a JD’s hydrophilic terminal
end groups could be modified with biochemical markers to find specific types of cancer cells, thus
further increasing the specificity of the vehicles.
Overall, our new PAMAM-fatty acid hybrid JD shows promising potential in combating
many of the numerous issues that have hindered the advancement of specific cancer treatments
including toxicity to healthy cells, potency, solubility, and stability.
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RESULTS AND DISCUSSION
DESIGN STRATEGY
PAMAM
Our PAMAM-fatty acid hybrid contains two dendritic moieties joined together via click
chemistry. PAMAM makes up the hydrophilic portion, and the fatty acids are hydrophobic (Figure
4). PAMAM is synthesized with alternating Michael additions and amidations using methyl
acrylate and ethylenediamine to create a branched polymer. Because of the stepwise repetition,
PAMAM can be synthesized to form varying sizes with different amounts of branching.

Figure 4. Example of the hybrid showing the hydrophilic (red) and hydrophobic (blue) moieties.
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PAMAM is also ideal for terminal functionalization. We have successfully functionalized
the terminal ends with three different groups (Figure 5). The functionalization of the PAMAM
surface is important to the toxicity of the vehicle.2,12 The repeating amide segments mimic the
makeup of biological molecules,2 however, exposed cationic amine groups are toxic to human
cells.21 The large positive charge rips the anionic cell membrane of human cells apart, therefore
it is harmful to healthy cells.21 However, it is beneficial to have a small overall positive charge to
encourage interaction between the DDS and cells.

PAMAM-TBE

PAMAM-BOC

PAMAM-THP

Figure 5. The three PAMAM moieties with TBE, BOC, and THP protection groups

The various end groups also allow the potential for other biochemical groups to be
covalently bonded to the ends of the PAMAM moiety. This could lead to advancements in
increasing specificity. For example, some forms of cancer overexpress biotin receptors on the cell
surface.22 By attaching biotin to the ends of PAMAM, the DDSs will be more likely to dock with
the cancer cells and unload the drugs at that specific location.22 The different biomarkers can be
11

chemically attached with a variety of reactions including acylation, Michael addition, and
amidation.23
The PAMAM dendron was synthesized using the divergent method. This method uses the
core as the starting point and grows the branches from this central molecule.2 The core functional
group for PAMAM is propargyl amine. The first half-generation of PAMAM is formed via a
Michael addition with the core and methyl acrylate. This step is followed by a nucleophilic
amidation with ethylenediamine to yield the first full generation. These steps are repeated to grow
the PAMAM dendron until generation 3 (Scheme S4). The amine-terminated generation 3 dendron
was treated with di-tert-butyl dicarbonate in methanol to obtain P-PAMAM-G3-BOC with 92%
yield. PAMAM generation 2.0 was treated with tertbutyl acrylate in methanol to obtain PPAMAM-G3-TBE with a 90% yield. PAMAM generation 2.5 was treated with ((tetrahydro-2Hpyran-2-yl)oxy)methanamine in methanol to obtain P-PAMAM-G3-THP with 81% yield (Figure
6).
TBE - tert-butyl ester

THP – tetrahydropyran

BOC- tert-butoxycarbonyl

Figure 6. End groups on the PAMAM moiety
FATTY ACIDS
The lipophilic fatty acid chains were chosen for their well-studied nature in human biology.
Fatty acids are used in the body to make up cell membranes, store energy, and make up other
macromolecules in the body. The biocompatibility and biodegradability make fatty acids a good
choice for creating nontoxic drug vehicles. Additionally, the fatty acid chains are responsible for
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the hydrophobic interactions that are the driving force for the self-assembly of the nanocarriers.
These are the same forces that create the bilayer of cell membranes in the human body, and
therefore show promise in increasing the stability and strength of DDSs.
The fatty acid portion contains an azide-bis-MPA-4 core with fatty acids esterified to the
four terminal alcohol groups. We chose fatty acids because of their potential enhancement of
mechanical properties of our DDSs. Fatty acids exhibit strong hydrophobic interactions which
have the potential to strengthen the stability of the vehicle and prevent early release of the drug. In
addition, fatty acids are a well-understood bio-molecule in the human body, thus the fatty acid
moiety is biocompatible.
The bis-MPA core is composed of polyesters, and it is first synthesized with a substitution
scheme to substitute an alcohol group with an azide to later perform the click reaction. Next, the
resulting A-MPA-2-OH is esterified with the bis-MPA monomer, followed by an acetal
deprotection to yield A-MPA-4-OH. The polymer’s terminal alcohol groups are esterified to form
the final A-bis-MPA-4-FA hydrophobic moiety (Scheme S2).
The hydrophobic, fatty acid moiety was also synthesized using the divergent method. The
core of the lipophilic dendron is an azide group, and the branches are grown using a bMPA
monomer. Using 1,1'-carbonyldiimidazole (CDI) to activate the carbonyl group and cesium
fluoride (CsF) as a catalyst, a Malkoch esterification yielded A-bis-MPA-OH-4. The 4 alcohol
groups were esterified with palmitoyl chloride to afford A-bis-MPA-FA-4 with a 91% yield
(Scheme S2). Presence of the azide group was confirmed by the FTIR using stretching vibrations
at 2102 cm-1 (Figure 7).
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-N3 peak

Figure 7. FTIR spectra for A-MPA-4-FA (10)

PAMAM-FA
After synthesizing both half-dendrons separately, they were linked via click chemistry. We
synthesized the core of the 2 dendrons to have a propargyl amine and an azide to covalently bind
them together using copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) (Figure 8). The
reaction was carried out with the hydrophobic dendron in excess to increase product yields. It also
is easier to separate the final JD from the hydrophobic portion due to the greater difference in
molar mass. This difference allows for separation of the two molecules via size exclusion
chromatography, a method that is somewhat different from previous methods described in
literature. Additionally, this method provided good yields of all three JDs (79-86%). After
purifying the product, the protecting groups on the terminal ends of the PAMAM moiety, TBE,
BOC, and THP, are removed using trifluoroacetic acid (TFA). The deprotection yields the final
Janus dendrimers: FA-PAMAM-NH3+, FA-PAMAM-COO- and FA-PAMAM-OH.
14

Figure 8. Synthetic route for amphiphilic JDs
1

H and

13

C NMR spectroscopy were used to monitor the reactions and to confirm the

intermediate products (Figure S1-S30). Additionally, 1H and

13

C NMR and GPC were used to

characterize the final synthetic ‘click’ products. FA-PAMAM-BOC is used to demonstrate the
characterization results of the compounds. The center triazole ring that forms during the click
reaction creates a new peak in the 1H NMR spectrum at 8.06 ppm that corresponds to H-3 (Figure
S24-S23). Additionally, the 13C NMR spectrum exhibits two new peaks at 144 and 125 ppm that
correspond to C-1 and C-2, respectively, of the triazole ring to further confirm the completion of
the click reaction (Figure 9). The protons at the α positions of the triazole ring, H-1, correspond to
the hydrophilic PAMAM moiety, and their peaks shift downfield from 3.62 to 4.40 ppm relative
to the starting PAMAM dendron (Figure S23). Similarly, the protons at the α positions of the
triazole ring, H-4, correspond to the hydrophobic fatty acid moiety, and their peaks shift downfield
from 3.32 to 4.29 relative to the starting fatty acid dendron (Figure S23). The peaks that correspond
to PAMAM (2.19-3.69 ppm) and bMPA fatty acid (1.57, 5.15 ppm) remained unchanged, and the
integrations for each peak accurately reflect both hydrophilic and hydrophobic moieties (Figure
S23).
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4

1
2
144.29

3
125.79

Figure 9. 13C NMR spectrum for FA-PAMAM-BOC in CDCl3 recorded at 400 MHz

Further characterization of the JDs was done using GPC (Table 1). In particular, GPC was
used to determine the monodispersity of the final product and confirm that there were no free,
unreacted dendrons that remained in solution after the CuAAC coupling process. GPC was run
using protected JDs due to their solubility in THF, and each compound’s results revealed a single
peak on the GPC chromatogram indicating that there is one macromolecule in solution and no free,
unreacted dendrons (Fig S31-S33). The shoulders that appear in the GPC data is due to the
hydrophilic branching of the JDs which interacts with the hydrophobic column and affects its
elution rate.11 In addition, the retention peak of the starting material does not correspond to the
shoulder on the final product, thus our data shows that we have no free dendrons that had not
reacted during the CuAAC process.
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TABLE 1. Molecular Weight Characterization of JDs by GPC with THF as the elution solvent;
chromatographs shown in the supporting information figures.
Mth g mol-1

FA-PAMAM-G3-BOC

3785

3625

3801

1.05

FA-PAMAM-G3-TBE

3096

3118

3289

1.06

FA-PAMAM-G3-THP

3665

3716

3781

1.02

a

Mn g mol-1

Mw g mol-1

Ða

Sample

Mth, Mn, Mw, Ð denote theoretical molar mass, number average molar mass, weight average molar
mass and dispersity, respectively. In GPC, the dispersity, Ð, refers to the distribution of the
molecular weight of a JD. It is measured as Mw/Mn, and an ideal value is 1.0.24
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SELF-ASSEMBLY AND MORPHOLOGY
TABLE 2. CAC values, the average hydrodynamic diameter of the dendritic aggregates by TEM
and DLS (in number and intensity), and surface charge.
PDIa

ζ-potential
(mV)

103.7 ± 40.3

0.191

56.1 ± 6.5

41.0 ± 9.0

53.3 ± 12.4
308.2 ± 85.1

0.469

8.5 ± 1.6

93.1 ± 15.9

102.2 ± 14.1

0.882

-17.9 ± 2.6

Sample

Dh(nm)
CAC
-1
(µmol L ) Number

Intensity

FA-PAMAM-G3-NH3+

1.9 ± 0.2

57.8 ± 16.7

FA-PAMAM-G3-OH

0.92 ± 0.2

FA-PAMAM-G3-COO-

0.92 ± 0.2

a

In DLS, the dispersity, or PDI, refers to the distribution of the different sizes of the aggregates. It
is measured as the square of the standard deviation divided by the mean, and the ideal value is
0.1.24

Self-assembly of the three different JDs was accomplished using the nanoprecipitation
method.25,26 Water was used for the formation of FA-PAMAM-NH3+ aggregates, and a PBS buffer
was used for the FA-PAMAM-COO- and FA-PAMAM-OH aggregates. After the nanoparticles
assembled, we measured the critical aggregation concentration (CAC) (Table 2, Figure S34-S35).
CAC values correlate to the concentration that determines if the JDs will remain self-assembled.
If the concentration is above the CAC, they will form the vehicle. Below this concentration, the
vehicle will not form. The CAC values are measured by using pyrene as a solvatochromic
fluorophore. Pyrene is a hydrophobic molecule that exhibits different fluorescent profiles
depending on if it is in water or in a lipophilic medium. If the JDs self-assemble, then pyrene will
aggregate in the lipophilic layer of the vehicle, and the appropriate fluorescent profile will be
detected. As a result, the CAC values can be measured. The CAC values can provide an indication
of the stability of the nanoparticle. A lower CAC value indicates a more stable vehicle relative to
a higher CAC. It is critical for the CAC to be relatively low due to the vehicles inevitable dilution
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when it enters the bloodstream. As shown in Table 2, the CAC ranged from 0.92 to 1.9 µmol/L.
These values are similar to the CAC values of other vehicles that are potential candidates for
biomedical applications.27,28
The CAC values for these macromolecules are all relatively low, but they do vary slightly
based on the surface charge. Positively charged FA-PAMAM-NH3+ has the largest CAC value (1.9
µmol/L), and anionic FA-PAMAM-COO- and FA-PAMAM-OH had the smaller value (0.92
µmol/L). These results suggest that the anionic and neutral JDs form more stable nanoparticles
than the cationic JD.
The corresponding diameters for the different JD aggregates were determined using
dynamic light scattering (DLS) (Table 2, Figure S31-S33). Here we include the number and
intensity value. The number diameter represents the diameter of the majority of the aggregates
formed. The intensity diameter is the average diameter of all the aggregates, but the value favors
the largest aggregates formed. Our research primarily focuses on the number diameter. Anionic
JDs have a larger particle size with the number average radii 93.1 nm, intensity average radii 102.2
nm with 0.882 PDI. For the neutral JD, number average radii 41.0 nm, intensity average DLS data
gave two distributions, small hydrodynamic diameters (53.3 nm), and larger hydrodynamic
diameter (308.2 nm) with 0.469 PDI (Figure S33). Cationic JD shows similar particle size to
neutral JD with number average radii 57.8 nm, intensity average radii 103.7 nm with 0.191 PDI.
Based on the PDI value, cationic JDs and neutral JDs show a narrow size distribution where PDI
values range from 0.1 to 0.5, and anionic JDs show a broad distribution with a PDI value greater
than 0.5. All particle sizes are below 200 nm, which indicates that they have the potential to escape
physiological barriers such as the enhanced permeability and retention effect. They also have a
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high potential for prolonged circulation and reduced filtration by the liver and spleen. Therefore,
these nanoparticles can be developed as drug gene delivery agents and cancer therapy agents.29
Because DLS data is reliant on the spherical shape of the nanoparticle, it is crucial to use
microscopic examination to determine the morphology. Cryo-TEM reveals the dendrimers’
behavior as predicted in aqueous solutions, and it exhibits the different morphologies of the selfassembled JD aggregates (Figure 10). All of the images show that the JDs form spherical
nanoparticles when they self-assemble, thus validating the DLS data. The images of FA-PAMAMG3-NH3+ (Figure 10a) showed spherical aggregates with an average particle size of 55.6 nm. The
images correlated with the DLS data that reported a single average radius of 57.8 nm. FAPAMAM-G3-OH (Figure 10b) formed spherical aggregates that were isolated, which had an
average particle size of 47.5 nm, and they formed clusters of nanoparticle aggregates. This
explained why the DLS data showed two average radii of 53.2 nm and 308.2 nm. Because DLS is
not designed to measure multimodal particle size distributions, the signal of the smaller particle is
much weaker. Finally, FA-PAMAM-G3-COO- (Figure 10c) assembled into spherical aggregates
with an average particle size of 104.8 nm. This value corresponds to the average radii of 93.1 nm
that was measured by DLS. In conclusion, the FA-PAMAM-OH JDs formed more aggregates
relative to the cationic and anionic JDs which could be due to the neutral surface charge. Unlike
the charged JDs, the neutral JD does not experience charge separation between the nanoparticles.
This contributes to the formation of more aggregates with the support of hydrogen bonding
between the terminal alcohol groups.
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Figure 10. Cryo-TEM images with utilizing uranyl formate as a contrast agent for (A) FAPAMAM-G3-NH3+, (B) FA-PAMAM-G3-OH and (C) FA-PAMAM-G3-COO-.
The zeta potentials were also studied to determine the surface charge of the aggregates
formed from the amphiphilic JDs (Table 2). FA-PAMAM-G3-NH3+ had a surface charge of 56.1
± 6.5 mV in Milli Q water at pH 7.0. FA-PAMAM-G3-COO- had a surface charge of -17.9 ± 2.6
mV at pH 7.4 in PBS buffer. Lastly, FA-PAMAM-G3-OH had a charge of 8.5 ± 1.6 mV at pH 7.4

21

in PBS solution. The resulting zeta potential values correspond to the expected values of each JD’s
respective terminal charge. In literature, particles with surface charges below 15 mV displayed the
ideal properties such as decreased macrophage uptake,30 higher tumor retention, and longer
circulation time.31 This indicates that our neutral JDs have a greater potential to exhibit these
properties, as well. Also, the ideal surface charge depends on factors such as cell type, cellular
uptake mechanism, and intracellular localization of nanoparticles.18,32 Therefore, the cationic and
anionic JDs have the potential to be useful for other applications in which a more positive or more
negative charge is needed.
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CONCLUSION
In this study, we successfully synthesized and characterized cationic, anionic, and neutral
amphiphilic PAMAM-fatty acid Janus dendrimers. TEM and DLS analysis indicate the size of
spherical nanoparticles ranging from 40 to 100 nm with zeta-potential values ranging from -17.9
to +58.7 mV concerning the terminal functional group. Further, these systems exhibited spherical
aggregates with critical aggregate concentrations ranging from 0.92 to 1.9 µmol/L. Of these three,
the neutral FA-PAMAM-OH had a low CAC value, and the zeta potential revealed an ideal surface
charge for future biomedical applications. This study showed that Janus dendrimers with neutral
surface charges exhibit characteristics that indicate their strong candidacy as potential drug
delivery systems. Further studies regarding drug loading capacity, pH studies, and cytotoxicity
still need to be conducted. Additional studies regarding the optimization of the vehicle could also
be conducted to determine the best hydrophilic to hydrophobic ratio to achieve ideal mechanical
properties. Finally, studies to investigate a synthetic route for JDs with two surface functionalities
would be beneficial for manipulating the surface charge. Although there is still work to be done in
the realm of cancer treatment, our results revealed new insights for progress in drug delivery
system research.
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SYNTHESIS SCHEMES

SYNTHETIC DETAILS

Scheme S1. Synthesis of 2,2,5-trimethyl-1,3-dioxane-5-carboxylic acid

Scheme S2. Synthesis of hydrophobic dendron

Scheme S3. Synthesis of ((tetrahydro-2H-pyran-2-yl)oxy)methanamine
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Scheme S4. Synthesis of hydrophilic dendron
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Reported below are the full synthetic details for the preparation of monomers, dendrons,
and amphiphilic Janus dendrimers
2,2,5-trimethyl-1,3-dioxane-5-carboxylic acid (2)
This procedure was adapted from previously reported procedures.1 To the stirred solution of 3hydroxy-2-(hydroxymethyl)-2-methylpropanoic acid (100.06 g, 0.750 mol) in 500 mL of acetone,
2,2-dimethoxypropane (DMP) (116.47 g, 1.12 mol) and p-toluenesulfonic acid (PTSA) (7.10 g,
37.2 mmol) were added under room temperature. After the completion of the addition, the reaction
mixture was stirred 5 h. Then it was filtered through an amberlyst column and the solvent was
evaporated at room temperature. The residue was recrystallized using CH2Cl2 to give (2) white
crystals with 92% yield (120.20 g). 1H NMR (500 MHz, CDCl3) δ 4.27 – 4.17 (m, 2H), 3.76 –
3.66 (m, 2H), 1.55 – 1.39 (m, 6H), 1.23 (d, J = 2.8 Hz, 3H).
(2,2,5-trimethyl-1,3-dioxan-5-yl)methanol (4)
This procedure was adapted from previously reported procedures.2 To the stirred solution of 2(hydroxymethyl)-2-methylpropane-1,3-diol (10.10 g, 84.0 mmol) in 50 mL of acetone, 2,2dimethoxypropane (DMP) (13.14 g, 0.126 mol) and PTSA (0.79 g, 0. 4.14 mmol) were added
under room temperature. After the completion of the addition, the reaction mixture was stirred 4
h. Then it was filtered through an amberlyst column and the solvent was evaporated, and the
residue was put under 60 oC and full vacuum for 2 h. Then it was put under vacuum overnight to
give (4) as a colourless liquid with 96% yield (12.91 g). 1H NMR (500 MHz, CDCl3) δ 3.67 (d, J
= 5.3 Hz, 4H), 3.60 (d, J = 11.8 Hz, 2H), 1.44 (s, 3H), 1.40 (s, 3H), 0.83 (s, 3H).
(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl 4-methylbenzenesulfonate (5)
This procedure was adapted from previously reported procedures.2 Compound (4) (10.89 g, 68.0
mmol) was dissolved in 34 ml of pyridine and it was added dropwise to the stirred solution of ptoluenesulfonyl chloride (35.70 g, 0.187 mol) in 48 mL of pyridine at 0 oC under nitrogen. After
the complete addition, reaction mixture was stirred 48 h at room temperature. Then the reaction
mixture was added dropwise to 100 ml of 40% ammonium chloride solution at 0 oC. After
complete addition, it was allowed to stir at room temperature for 2 h. Then it was filtered and
washed with DI water until the pyridine smell was gone. Then the residue was dissolved in 25 ml
of DCM and extracted with half saturated ammonium chloride and saturated NaCl solution.
Yellow DCM solution was dried with anhydrous sodium sulfate. Then the solvent was evaporated,
and the residue was placed under full vacuum for 12 h to give (5) as a yellow solid with 89% yield
(19.02 g). 1H NMR (500 MHz, CDCl3) δ 7.86 – 7.79 (m, 2H), 7.38 (d, J = 7.6 Hz, 2H), 4.11 (s,
2H), 3.58 (s, 4H), 2.47 (s, 3H), 1.39 (d, J = 4.8 Hz, 3H), 1.25 (d, J = 4.7 Hz, 3H), 0.84 (s, 3H).
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5-(azidomethyl)-2,2,5-trimethyl-1,3-dioxane (6)
This procedure was adapted from previously reported procedures.2 Compound 5 (14.60 g, 46.4
mmol), NaN3 (12.07 g, 186 mmol), water (10 mL), and DMF (80 mL) were stirred at 110 °C for
48 h under reflux. The mixture was poured into 150 ml water and extracted four times with Et 2O
(4 × 200 mL). The organic phase was dried over anhydrous MgSO4 and the solvent was removed
under reduced pressure. The residue was purified by column chromatography with silica gel (100
g) and ethyl acetate/n-hexane (1:4) to give 7.48 g of a colourless liquid with an 87% yield. 1H
NMR (500 MHz, CDCl3) δ 3.58 (d, J = 2.8 Hz, 4H), 3.51 (s, 2H), 1.40 (d, J = 13.8 Hz, 6H), 0.81
(d, J = 1.1 Hz, 3H).
2-(azidomethyl)-2-methylpropane-1,3-diol (7)
This procedure was adapted from previously reported procedures.4 Compound (6) (7.05 g, 40.2
mmol) was dissolved in 35 ml of methanol. 7.00 g of a Dowex, H+ resin was added, and the
reaction mixture was stirred for 12 h at 50 oC. When the reaction was complete the Dowex, H+
resin was filtered off in a vacuum filter under a low vacuum and carefully washed with methanol.
The methanol was evaporated to give 5.41 g of white crystals with a 93% yield. 1H NMR (400
MHz, CDCl3) δ 3.73 – 3.58 (m, 4H), 3.56 – 3.43 (m, 2H), 2.19 (s, 2H), 0.89 (d, J = 2.0 Hz, 3H).
A-MPA-4-AC (8)
This procedure was adapted from previously reported procedures.3 Compound 2 (6.48 g, 37.2
mmol), 1,1'-carbonyldiimidazole (CDI) (9.05 g, 55.8 mmol) were dissolved in 30 ml of ethyl
acetate and it was stirred 1 h at 50 °C. CsF (0.75 g, 4.93 mmol), Compound (7) (1.80 g, 12.4 mmol)
were dissolved in 10 ml of ethyl acetate separately and it was slowly added to the reaction mixture
under nitrogen at 50 oC. It was stirred 12 h. When the reaction was complete 200 ml DI water was
added and allowed to stir 2 h at room temperature. Then it was extracted with 1 M HCl (200 ml x
3), 1 M NaHSO4 (200 ml x 3), 10% Na2CO3, saturated NaCl (200 ml) and it was dried under
anhydrous MgSO4. Ethyl acetate was evaporated to give 5.22 g of colourless oil liquid with a 92%
yield. 1H NMR (500 MHz, CDCl3) δ 4.21 (d, J = 11.7 Hz, 4H), 4.13 – 4.09 (m, 4H), 3.68 (d, J =
11.7 Hz, 4H), 3.42 – 3.39 (m, 2H), 1.43 (d, J = 32.2 Hz, 12H), 1.18 (d, J = 1.6 Hz, 6H), 1.08 (d, J
= 1.5 Hz, 3H).
A-MPA-4-OH (9)
This procedure was adapted from previously reported procedures.4 Compound (8) (5.00 g, 10.9
mmol) was dissolved in 20 ml of methanol. 5.00 g of a Dowex, H+ resin was added, and the
reaction mixture was stirred for 12 h at 50 oC. When the reaction was complete the Dowex, H+
resin was filtered off in a vacuum filter under a low vacuum and carefully washed with methanol.

27

The methanol was evaporated to give 3.96 g of colourless liquid with a 96% yield. 1H NMR (300
MHz, CDCl3) δ 4.09 (s, 4H), 3.88 (d, J = 11.2 Hz, 4H), 3.78 – 3.67 (m, 4H), 3.43 (s, 4H), 3.38 (s,
2H), 1.12 – 1.09 (m, 6H), 1.09 – 1.07 (m, 3H).
A-MPA-4-FA (10)
This procedure was adapted from previously reported procedures.1 To the stirred solution of (9)
(3.25 g, 8.61 mmol), TEA (13.94 g, 138 mmol), 4-dimethylaminopyridine (DMAP) (3.15 g, 25.8
mmol) in 50 ml DCM at 0 oC under nitrogen, palmitoyl chloride (18.93 g, 68.9 mmol) was
dissolved in 20 ml DCM and it was added dropwise. After the complete addition, it was stirred 12
h at room temperature. 150 ml of DI water was added, and it was stirred 1 h. Then the DCM layer
was separated, and it was dried under anhydrous MgSO4. DCM was evaporated to give yellow
residue further purified by the Sephadex-LH-20 column in DCM to give 10.86 g of yellow solid
with a 91% yield. 1H NMR (300 MHz, CDCl3) δ 4.22 (d, J = 1.5 Hz, 8H), 4.01 (s, 4H), 3.32 (s,
2H), 2.30 (t, J = 7.5 Hz, 8H), 1.59 (t, J = 7.4 Hz, 8H), 1.31 (d, J = 5.8 Hz, 104H), 1.04 – 0.99 (m,
3H), 0.91 – 0.86 (m, 18H).
((tetrahydro-2H-pyran-2-yl)oxy)methanamine (11)
This procedure was adapted from previously reported procedures.5 To the stirred solution of 2Benzylaminoethanol (5.0 g, 33.1 mmol) in 17 mL of DCM at 0 oC, methanesulfonic acid (3.50 g,
36.4 mmol) was added at 15 oC. After 45 min 3,4-dihydro-2H-pyran (4.73 g, 56.2 mmol) was
added at 10-15 oC. It was stirred for 1 h at 15 oC. Upon 1H NMR confirmation of completion, 3 N
caustic solution (17 mL, 49.1 mmol) was added at 5-10 oC. The phases were separated, and the
organic layer was concentrated in the vacuum line. The oily yellow crude product was purified by
short path distillation at 3 x 103 mbar and 117-125 oC. 1.0 g of crude product was dissolved in 15
mL of ethanol and Pd/C (5 wt%, 327 mg, 0.154 mmol) was added at room temperature overnight
under hydrogen balloon. Upon 1H NMR confirmation of completion, the reaction mixture was
filtered through a celite pad. Then the filtrate was concentrated in vacuum to give 0.53 g of
compound 11 with 86 % yield. 1H NMR (500 MHz, CDCl3) δ 4.66 – 4.58 (m, 1H), 3.94 – 3.75
(m, 2H), 3.64 (dt, J = 16.4, 5.9 Hz, 1H), 3.58 – 3.40 (m, 2H), 2.90 (q, J = 11.8, 8.7 Hz, 2H), 1.89
– 1.69 (m, 2H), 1.61 – 1.56 (m, 4H).
P-PAMAM-G-0.5 (12)
To the stirred solution of propargyl amine (5.10 g, 0.0800 mmol) in 50 mL of methanol, methyl
acrylate (MA) (35.38 g, 0.410 mmol) in 150 mL of methanol was added dropwise under-salted
ice. After the completion of the addition, the reaction mixture was allowed to come to room
temperature and then was subjected to heating at 35 oC overnight. Upon 1H NMR confirmation of
completion, MA was co-evaporated in-vacuo three times with butanol, three washes with reagent
alcohol, and three with MeOH until complete removal was confirmed by 1H NMR in CDCl3 with
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97% yield. 1H NMR (500 MHz, Chloroform-d) δ 3.65 (d, J = 3.5 Hz, 6H), 2.82 (q, J = 7.0, 5.3 Hz,
4H), 2.45 (q, J = 7.0, 5.2 Hz, 4H), 2.19 (t, J = 2.9 Hz, 1H).
P-PAMAM-G-1.0 (13)
To the stirred solution of ethylenediamine (EDA) (52.1 g, 0.866 mmol) in 100 mL of methanol,
12 (5.09 g, 0.0220 mmol) in 50 mL of methanol was added dropwise under-salted ice. After the
completion of the addition, the reaction mixture was allowed to come to room temperature and
then was subjected to heating at 35 oC overnight. Upon 1H NMR confirmation of completion, MA
was co-evaporated in-vacuo three times each with butanol, reagent alcohol, and MeOH until
complete removal was confirmed by 1H NMR in MeOD with 90% yield. 1H NMR (500 MHz,
MeOD) δ 3.58 (t, J = 6.5 Hz, 5H), 3.53 – 3.47 (m, 2H), 3.28 (t, J = 6.2 Hz, 4H), 2.86 (t, J = 6.7 Hz,
5H), 2.75 (t, J = 6.2 Hz, 5H), 2.65 (t, J = 2.6 Hz, 1H), 2.41 (t, J = 6.7 Hz, 4H), 2.20 (t, J = 2.9 Hz,
1H).
P-PAMAM-G-1.5 (14)
To the stirred solution of MA (53.30 g, 0.620 mmol) in 200 mL of methanol, 13 (5.94 g, 0.0620
mmol) in 50 mL in methanol was added dropwise under-salted ice. After the completion of the
addition, the reaction mixture was allowed to come to room temperature and then was subjected
to heating at 35 oC for two days. Upon 1H NMR confirmation of completion, MA was coevaporated in-vacuo three times with butanol, three with reagent alcohol, and three with MeOH
until complete removal was confirmed by 1H NMR in CDCl3 with 95% yield. 1H NMR (500 MHz,
CDCl3) δ 3.70 (d, J = 1.5 Hz, 13H), 3.49 (d, J = 2.2 Hz, 2H), 3.32 (q, J = 5.8 Hz, 4H), 2.88 (t, J =
6.7 Hz, 4H), 2.79 (t, J = 6.6 Hz, 9H), 2.57 (t, J = 6.0 Hz, 3H), 2.46 (t, J = 6.7 Hz, 9H), 2.41 (t, J =
6.8 Hz, 4H), 2.19 (t, J = 2.9 Hz, 1H).
P-PAMAM-G-2.0 (15)
To the stirred solution of EDA (47.56 g, 793 mmol) in 100 mL of methanol, 14 (12.51g, 9.87
mmol) in 60 mL in methanol was added dropwise under-salted ice. After the completion of the
addition, the reaction mixture was allowed to come to room temperature and then it was subjected
to heating at 35 oC for three days. Upon 1H NMR confirmation of completion, MA was coevaporated in-vacuo three times with butanol, three with reagent alcohol, and three with MeOH
until complete removal was confirmed by 1H NMR in MeOD with 91% yield. 1H NMR (500 MHz,
CDCl3) δ 3.56 (t, J = 6.7 Hz, 12H), 3.39 (t, J = 4.7 Hz, 2H), 3.21 (m, J = 12.0, 6.0 Hz, 8H), 2.76
(t, J = 5.9 Hz, 8H), 2.69 (dd, J = 11.0, 4.7 Hz, 8H), 2.47 (t, J = 6.2 Hz, 2H), 2.29 (d, J = 21.8 Hz,
18H), 2.20 (t, J = 2.9 Hz, 1H).
P-PAMAM-G-2.5 (16)
To the stirred solution of MA (71.84 g, 834 mmol) in 150 mL of methanol, 15 (12.45 g, 16.7
mmol) in 60 mL in methanol was added dropwise under-salted ice. After the completion of the
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addition, the reaction mixture was allowed to come to room temperature and then it was subjected
to heating at 35 oC for four days. Upon 1H NMR confirmation of completion, MA was coevaporated in-vacuo three times with butanol, three with reagent alcohol, and three with MeOH
until complete removal was confirmed by 1H NMR in CDCl3 with 94% yield. 1H NMR (300 MHz,
CDCl3) δ 3.68 (s, 24H), 3.47 (s, 2H), 3.30 (d, J = 5.8 Hz, 12H), 2.79 (dt, J = 13.6, 6.5 Hz, 28H),
2.57 (dt, J = 12.2, 6.0 Hz, 12H), 2.44 (t, J = 6.7 Hz, 16H), 2.38 (t, J = 6.3 Hz, 12H), 2.19 (t, J = 2.9
Hz, 1H).
P-PAMAM-G-3.0 (17)
To the stirred solution of EDA (34.31 g, 571 mmol) in 70 mL of methanol, 16 (10.24 g, 7.14 mmol)
in 50 mL in methanol was added dropwise under-salted ice. After the completion of the addition,
the reaction mixture was allowed to come to room temperature and then it was subjected to heating
at 35 oC for four days. Upon 1H NMR confirmation of completion, MA was co-evaporated invacuo three times with butanol, three with reagent alcohol, and three with MeOH until complete
removal was confirmed by 1H NMR in MeOD with an 88% yield. 1H NMR (500 MHz, MeOD) δ
3.57 (t, J = 6.7 Hz, 4H), 3.39 – 3.34 (m, 16H), 3.32 – 3.26 (m, 28H), 2.81 (tq, J = 12.8, 6.4 Hz,
48H), 2.61 (q, J = 6.8 Hz, 14H), 2.39 (t, J = 7.0 Hz, 30H).
P-PAMAM-TBE (18)
To the stirred solution of 15 (22.00 g, 29.7 mmol) in 110 mL of methanol, tertbutyl acrylate (TBA)
(190.53 g, 149 mmol) in 380 mL methanol was added dropwise under-salted ice. After the
complete addition of TBA, the reaction was allowed to warm to room temperature. The reaction
continued at room temperature for two days. Upon 1H NMR confirmation of completion, a single
rotovap ensued. The PAMAM product was dissolved into a minimal amount of DCM which was
followed by precipitation via separatory funnel into 5x mL of stirring, pure hexane. After settling,
the hexane layer was decanted, and the remaining product was air-dried. This precipitation,
decanting, and the air-drying process was repeated twice more. A final 1H NMR ensured the
removal of TBA with 90% yield. 1H NMR (500 MHz, CDCl3) δ 3.47 (s, 2H), 3.35 (s, 18H), 3.26
(s, 26H), 2.74 (s, 24H), 2.56 (d, J = 15.4 Hz, 14H), 2.37 (s, 28H), 2.19 (t, J = 2.9 Hz, 1H), 1.45 (s,
72H).
P-PAMAM-BOC (19)
To the stirred solution of 17 (15.06 g, 9.04 mmol) in 150 mL of methanol, di-tert-butyl dicarbonate
(Boc Anhydride) (39.85 g, 0.182 mmol) in 120 mL in methanol was added dropwise under-salted
ice. After the complete addition of Boc Anhydride, the reaction was allowed to warm to room
temperature. The reaction continued at room temperature for two days. Upon 1H NMR
confirmation of completion, a single rotovap ensued. The PAMAM product was dissolved into a
minimal amount of DCM which was followed by precipitation via separatory funnel into 5x mL
of stirring, pure hexane. After settling, the hexane layer was decanted, and the remaining product
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was air-dried. This precipitation, decanting, and the air-drying process was repeated twice more.
A final 1H NMR ensured the removal of Boc Anhydride with a 92% yield. 1H NMR (400 MHz,
CDCl3) δ 3.62 (s, 2H), 3.32 (q, J = 5.6 Hz, 18H), 3.24 (t, J = 6.2 Hz, 28H), 2.80 – 2.65 (m, 28H),
2.53 (q, J = 7.9, 6.0 Hz, 14H), 2.36 (q, J = 9.0, 6.7 Hz, 28H), 2.23 (s, 1H), 1.42 (s, 72H).
P-PAMAM-THP (20)
To the stirred solution of 16 (15.06 g, 9.04 mmol) in 150 mL of methanol, ((tetrahydro-2H-pyran2-yl)oxy)methanamine (THP) (11) (39.85 g, 0.182 mmol) in 120 mL in methanol was added
dropwise under-salted ice. After the complete addition of THP, the reaction was allowed to warm
to room temperature. The reaction continued at room temperature for four days. Upon 1H NMR
confirmation of completion, a single rotovap ensued. The PAMAM product was dissolved into a
minimal amount of DCM which was followed by precipitation via separatory funnel into 5x mL
of stirring, pure hexane. After settling, the hexane layer was decanted, and the remaining product
was air-dried. This precipitation, decanting, and the air-drying process was repeated twice more.
It was further purified using size exclusion chromatography (Sephadex LH-20). A final 1H NMR
ensured the removal of excess THP with 81% yield. 1H NMR (500 MHz, CDCl3) δ 4.57 (s, 8H),
3.94 – 3.72 (m, 18H), 3.48 (d, J = 31.1 Hz, 28H), 3.34 (s, 12H), 2.97 – 2.61 (m, 24H), 2.36 (s,
16H), 1.81 (s, 52H), 1.63 – 1.36 (m, 48H).
Reported below are the full synthetic details for the preparation of macromolecules
FA-PAMAM-NH3+
To the stirred solution of P-PAMAM-Boc (3.20 g, 1.31 mmol), A-MPA-4-FA (2.72 g, 1.957
mmol) in 25 ml of DMF, CuBr (374.0 mg, 2.61 mmol) was added under nitrogen flushing. After
complete addition, N,N,N′,N′′,N′′-Pentamethyldiethylenetriamine (PMDETA) (452.2 mg, 2.61
mmol) was added and allowed to stir under nitrogen at 35 oC for 48 h. The reaction mixture was
precipitated to 200 ml diethyl ether. After settling, the diethyl ether layer was decanted, and the
remaining product was air-dried. This precipitation, decanting, and the air-drying process was
repeated twice more. The crude product was dissolved in 100 ml of DCM. It was extracted with
0.1 M EDTA solution. It was further purified using size exclusion chromatography (Sephadex LH20) to give 3.95 g of FA-PAMAM-BOC. It was dissolved in 45 ml of chloroform and 4.5 mL (10%
v/v) of trifluoroacetic acid (TFA) was slowly added and stirred for 45 minutes. The reaction
mixture was air-dried and dissolved in 10 mL of chloroform. It was added dropwise to 500 mL of
diethyl ether and stirred for 2 h. It was filtered and precipitation procedure was repeated three
times. Finally, the resulting yellow solid was put under the vacuum for 24 hours to obtain the pure
product with 86% yield. 1H NMR for FA-PAMAM-Boc (500 MHz, CDCl3) δ 7.87 (s, 1H), 5.875.70 (m, 8H), 4.40 (s, 2H), 4.29 (s, 2H), 4.26 (s, 4H), 4.23 (s, 8H), 3.31 (m, 28H), 3.23 (m, 18H),
2.81 (m, 28H), 2.49 (m, 14H), 2.29 (q, 28H) ,1.42 (s, 72H), 1.30-1.22 (m, 104H), 1.01 (s, 3H),
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0.98 (s, 6H), 0.86 (t, 12H). 13C NMR (101 MHz, Chloroform-d) δ 172.99, 172.07, 156.40, 144.29,
125.79, 78.99, 77.40, 64.87, 52.45, 47.84, 44.21, 33.97, 31.81, 29.58, 24.80, 22.56, 17.73, 13.95.
FA-PAMAM-COOH
To the stirred solution of P-PAMAM-TBE (2.50 g, 1.32 mmol), A-MPA-4-FA (1.67 g, 1.29 mmol)
in 25 ml of DMF, CuBr (374.0 mg, 2.61 mmol) was added under nitrogen flushing. After complete
addition, PMDETA (452.2 mg, 2.61 mmol) was added and allowed to stir under nitrogen at 35 oC
for 48 h. The reaction mixture was precipitated to 200 ml diethyl ether. After settling, the diethyl
ether layer was decanted, and the remaining product was air-dried. This precipitation, decanting,
and the air-drying process was repeated twice more. The crude product was dissolved in 100 ml
of DCM. It was extracted with 0.1 M EDTA solution. It was further purified using size exclusion
chromatography (Sephadex LH-20) to give FA-PAMAM-TBE as a yellow solid. Then 2 g of FAPAMAM-TBE was dissolved in 30 ml of chloroform and 3.0 mL (10% v/v) of TFA was added
dropwise and stirred for 45 minutes. The reaction mixture was air-dried and dissolved in 8 mL of
chloroform. It was added dropwise to 500 mL of diethyl ether and stirred for 2 h. It was filtered
and precipitation procedure was repeated three times. Finally, the resulting yellow solid was put
under the vacuum for 24 h to obtain the pure product with 82% yield. 1H NMR for FA-PAMAMTBE (400 MHz, CDCl3) δ 7.82 (s, 1H), 5.91-5.60 (m, 4H), 4.39 (s, 2H), 4.29 (s, 2H), 4.26 (s, 4H),
4.22 (s, 8H), 4.01 (s, 8H), 3.32 (m, 18H), 3.22 (m, 26H), 2.84 (s, 24H), 2.47 (s, 28H), 2.30 (t, 14H),
1.42 (s, 72H), 1.27 – 1.24 (m, 104H), 1.01 (s, 3H), 0.98 (s, 6H), 0.89 – 0.87 (m, 14H).13C NMR
(126 MHz, CDCl3) δ 173.13, 171.92, 162.49, 142.91, 125.24, 66.00, 64.86, 52.81, 52.49, 51.60,
49.19, 46.47, 37.16, 36.42, 34.60, 29.65, 25.21, 24.81, 17.82, 14.05.
FA-PAMAM-OH
To the stirred solution of P-PAMAM-THP (1.04 g, 0.428 mmol), A-MPA-4-FA (0.86 g, 0.642
mmol) in 10 ml of DMF, CuBr (130.0 mg, 0.856 mmol) was added under nitrogen flushing. After
complete addition, PMDETA (149.4 mg, 0.856 mmol) was added and allowed to stir under
nitrogen at 35 oC for 48 h. The reaction mixture was precipitated to 200 ml diethyl ether. After
settling, the diethyl ether layer was decanted, and the remaining product was air-dried. This
precipitation, decanting, and the air-drying process was repeated twice more. The crude product
was dissolved in 100 ml of DCM. It was extracted with 0.1 M EDTA solution. It was further
purified using size exclusion chromatography (Sephadex LH-20) to give 1.27 g of a solid. Then
1g of FA-PAMAM-THP was dissolved in 15 ml of chloroform and 2.0 mL of TFA was added
dropwise and stirred for 60 minutes. The reaction mixture was air-dried and dissolved in 5 mL of
chloroform. It was added dropwise to 250 mL of diethyl ether:methanol mixture (2:1) and stirred
for 2 h. It was filtered and precipitation procedure was repeated three times. Finally, the resulting
yellow solid was put under the vacuum for 24 h to obtain the pure product with a 79 % yield. 1H
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NMR for FA-PAMAM-THP (400 MHz, CDCl3) δ 7.89 (s, 1H), 4.60 (s, 8H), 4.25 (s, 8H), 3.89 (s,
28H), 3.55 (s, 18H), 2.32 (s, 12H), 1.36 – 1.23 (m, 104H), 0.91 (s, 18H). 13C NMR (101 MHz,
Chloroform-d) δ 174.10, 172.96, 162.45, 142.04, 125.99, 98.88, 77.32, 66.30, 65.08, 63.76, 54.91,
46.50, 39.57, 34.05, 31.95, , 29.72, 25.47, 22.73, 22.71, 19.69, 17.87, 13.96.
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NMR SPECTRA

Figure S1. 1H NMR for 2,2,5-trimethyl-1,3-dioxane-5-carboxylic acid (2) (500 MHz, CDCl3)

Figure S2. 1H NMR for (2,2,5-trimethyl-1,3-dioxan-5-yl)methanol (4) (500 MHz, CDCl3)
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Figure S3. 1H NMR for (2,2,5-trimethyl-1,3-dioxan-5-yl)methyl 4-methylbenzenesulfonate (5)
(500 MHz, CDCl3)

Figure S4. 1H NMR for 5-(azidomethyl)-2,2,5-trimethyl-1,3-dioxane (6) (500 MHz, CDCl3)
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Figure S5. 1H NMR for 2-(azidomethyl)-2-methylpropane-1,3-diol (7) (400 MHz, CDCl3)

Figure S6. 1H NMR for A-MPA-4-AC (8) (400 MHz, CDCl3)
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Figure S7. 1H NMR for A-MPA-4-OH (9) (400 MHz, CDCl3)

Figure S8. 1H NMR for A-MPA-4-FA (10) (400 MHz, CDCl3)
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Figure S9. FTIR spectra for A-MPA-4-FA (10)

Figure S10. 1H NMR for ((tetrahydro-2H-pyran-2-yl)oxy)methanamine (11) (500 MHz, CDCl3)
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Figure S11. 1H NMR for P-PAMAM-G0.5 (500 MHz, CDCl3)

Figure S12. 1H NMR for P-PAMAM-G1.0 (500 MHz, MeOD)
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Figure S13. 1H NMR for P-PAMAM-G1.5 (500 MHz, CDCl3)

Figure S14. 1H NMR for P-PAMAM-G2.0 (500 MHz, MeOD)
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Figure S15. 1H NMR for P-PAMAM-G2.5 (500 MHz, CDCl3)

Figure S16. 1H NMR for P-PAMAM-TBE (300 MHz, CDCl3)
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Figure S17. 1H NMR for P-PAMAM-BOC (400 MHz, CDCl3)

Figure S18. 1H NMR for P-PAMAM-G-3.0-THP (500 MHz, CDCl3)
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Figure S19. 1H NMR comparison for FA-PAMAM-TBE with P-PAMAM-TBE and A-MPA-4FA (500 MHz, CDCl3)

Figure S20. 1H NMR for FA-PAMAM-TBE (500 MHz, CDCl3)
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Figure S21. 13C NMR for FA-PAMAM-TBE (300 MHz, CDCl3)

Figure S22. 1H NMR comparison for (a) FA-PAMAM-TBE, (b) FA-PAMAM-COOH (500 MHz,
CDCl3)
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Figure S23. 1H NMR comparison for FA-PAMAM-BOC with P-PAMAM-BOC and A-MPA-4FA (500 MHz, CDCl3)

Figure S24. 1H NMR for FA-PAMAM-BOC (500 MHz, CDCl3)
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Figure S25. 13C NMR for FA-PAMAM-BOC (400 MHz, CDCl3)

Figure S26. 1H NMR comparison for (a) FA-PAMAM-BOC, (b) FA-PAMAM-NH3+ (500 MHz,
CDCl3)
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Figure S27. 1H NMR comparison for FA-PAMAM-THP with P-PAMAM-THP and A-MPA-4FA (500 MHz, CDCl3)

Figure S28. 1H NMR for FA-PAMAM-THP (500 MHz, CDCl3)
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Figure S29. 13C NMR for FA-PAMAM-THP (400 MHz, CDCl3)

(a)

Figure S30. 1H NMR comparison for (a) FA-PAMAM-THP, (b) FA-PAMAM-OH (500 MHz,
CDCl3
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GPC CHROMATOGRAPHS

Figure S31. GPC chromatograms for 4-FA-PAMAM-BOC in THF

Figure S32. GPC chromatograms for 4-FA-PAMAM-TBE in THF

Figure S30. GPC chromatograms for 4-FA-PAMAM-THP in THF
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DLS SPECTRA

Figure S31. DLS spectra for FA-PAMAM-G3-NH3+, left: Size distribution by number, right: Size
distribution by intensity

Figure S32. DLS spectra for FA-PAMAM-G3-COO-, left: Size distribution by number, right: Size
distribution by intensity

Figure S33. DLS spectra for FA-PAMAM-G3-OH, left: Size distribution by number, right: Size
distribution by intensity
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CAC DATA

Figure S34. Excitation ratio vs. log concentration for FA-PAMAM-G3-NH3+ (left) and FAPAMAM-G3- COO- (right)

Figure S35. Excitation ratio vs. log concentration for FA-PAMAM-G3-OH
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